Horizon Discovery Announces Leadership Changes
February 20 2018 - 6:01AM
Horizon Discovery Announces Leadership
Changes
Cambridge, UK, 20 February 2018: Horizon
Discovery Group plc (LSE: HZD) ("Horizon", "the Company", or "the
Group"), a global leader in gene editing and gene modulation
technologies, today announces that Dr. Darrin M. Disley has decided
to step down as Chief Executive Officer in order to pursue other
business interests. As a consequence, the Chairman of the Board,
Dr. Ian Gilham, will assume the role of Executive Chairman and
Richard Vellacott, Chief Financial Officer and Deputy CEO, will
become Chief Executive Officer, both in an interim capacity.
A search for a CEO successor will begin immediately.
Commenting on the announcement, Dr. Ian
Gilham, Chairman of the Board of Directors, Horizon Discovery,
said: "I would like to express my sincere appreciation for
Darrin's achievements as CEO since he joined in 2007 when Horizon
was a start-up company through to now being a global leader in gene
editing and gene modulation. During his tenure, he has built a
world-class management team, set a highly successful commercial and
business strategy, led the Company through several financing
rounds, including the Company's successful IPO in 2014, and driven
multiple acquisitions including the Company's recent
transformational deal with Dharmacon. We support Darrin's decision
to step down at this time. We look forward, in due course, to
announcing the appointment of a new CEO who will lead the Company
through the next phase of its growth and development."
Dr. Darrin M Disley, said: "I am proud to
have led the team through this successful period and feel now is
the right time, after 11 years as Chief Executive Officer, to hand
over the reins to pursue my other business interests. I know the
Group and the current leadership team is the strongest it has ever
been. I wish everyone well and look forward to watching Horizon's
future successes."
Richard Vellacott, Interim Chief Executive
Officer, Horizon Discovery, said: "Horizon has never been in a
stronger position operationally and I would like to thank Darrin
for everything he has contributed to Horizon over the past many
years - he has been truly inspirational in the evolution of our
strategy and the rapid growth of the business, which is now a
global leader in gene editing and gene modulation. I look forward
to working closely with our focused and strong leadership
team."
Due to the leadership changes, the Group's
Capital Markets Day scheduled for 20 February 2018 will now take
place on 5 March 2018.ENDS
For further information from Horizon Discovery Group plc,
please contact:
Horizon Discovery Group plcIan Gilham,
Chairman Richard Vellacott, Interim Chief Executive OfficerTel: +44
(0) 1223 655 580
Numis Securities Limited (Broker and
NOMAD)Michael Meade / Freddie BarnfieldTel: +44 (0) 207 260
1000
Consilium Strategic Communications (Financial
Media and Investor Relations)Mary-Jane Elliott / Matthew Neal /
Melissa GardinerTel: +44 (0) 20 3709 5701Email:
horizon@consilium-comms.com
Zyme Communications (Trade and Regional
Media)Katie OdgaardTel: +44 (0)7787 502 947Email:
katie.odgaard@zymecommunications.com
About Horizon Discovery Group plc
www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD)
("Horizon") is a world leader in gene editing and gene modulation
technologies. Horizon designs and engineer's cells using its
translational genomics platform, a highly precise and flexible
suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and,
following the acquisition of Dharmacon, Inc., its functional
genomics platform comprising gene knockdown (RNAi) and gene
expression (cDNA, ORF) tools, for research and clinical
applications that advance human health. Horizon's platforms and
capabilities enable researchers to alter almost any gene or
modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue
products and related research services to support a greater
understanding of the function of genes across all species and the
genetic drivers of human disease and the development of
personalised molecular, cell and gene therapies. These have been
adopted by over 10,000 academic, drug discovery, drug manufacturing
and clinical diagnostics customers around the globe, as well as in
the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and
is listed on the London Stock Exchange's AIM market under the
ticker "HZD"
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024